NZ616992A - Anti-ilt7 antibody - Google Patents

Anti-ilt7 antibody

Info

Publication number
NZ616992A
NZ616992A NZ616992A NZ61699206A NZ616992A NZ 616992 A NZ616992 A NZ 616992A NZ 616992 A NZ616992 A NZ 616992A NZ 61699206 A NZ61699206 A NZ 61699206A NZ 616992 A NZ616992 A NZ 616992A
Authority
NZ
New Zealand
Prior art keywords
ilt7
human
binds
accession number
deposited under
Prior art date
Application number
NZ616992A
Other languages
English (en)
Inventor
Minkwon Cho
Koji Ishida
Naoko Arai
Yumiko Kamogawa
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of NZ616992A publication Critical patent/NZ616992A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
NZ616992A 2005-12-20 2006-12-20 Anti-ilt7 antibody NZ616992A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
NZ599683A NZ599683A (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody

Publications (1)

Publication Number Publication Date
NZ616992A true NZ616992A (en) 2015-07-31

Family

ID=38188642

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ616992A NZ616992A (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody
NZ569910A NZ569910A (en) 2005-12-20 2006-12-20 Anti-ILT7 antibody
NZ599683A NZ599683A (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ569910A NZ569910A (en) 2005-12-20 2006-12-20 Anti-ILT7 antibody
NZ599683A NZ599683A (en) 2005-12-20 2006-12-20 Anti-ilt7 antibody

Country Status (29)

Country Link
US (6) US8084585B2 (enExample)
EP (4) EP2532681B1 (enExample)
JP (2) JP5020828B2 (enExample)
KR (3) KR101585532B1 (enExample)
CN (5) CN110776566B (enExample)
AU (1) AU2006328470B2 (enExample)
BR (1) BRPI0620141B1 (enExample)
CA (2) CA2634116C (enExample)
CY (3) CY1114227T1 (enExample)
DK (3) DK2532681T3 (enExample)
ES (3) ES2416716T3 (enExample)
HK (1) HK1218126A1 (enExample)
HR (2) HRP20130494T1 (enExample)
HU (1) HUE039865T2 (enExample)
IL (1) IL192266A (enExample)
LT (1) LT2913343T (enExample)
ME (1) ME02111B (enExample)
MX (1) MX2008007682A (enExample)
NZ (3) NZ616992A (enExample)
PL (3) PL1964852T3 (enExample)
PT (3) PT2532681E (enExample)
RS (2) RS52860B (enExample)
RU (2) RU2456298C2 (enExample)
SG (2) SG170749A1 (enExample)
SI (3) SI2913343T1 (enExample)
TR (1) TR201816574T4 (enExample)
UA (1) UA97946C2 (enExample)
WO (1) WO2007072866A1 (enExample)
ZA (1) ZA200805850B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
MY171234A (en) 2010-02-24 2019-10-04 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
US9096660B2 (en) 2010-04-26 2015-08-04 Abraxis Bioscience, Llc SPARC binding antibodies and uses thereof
EP3318273B1 (en) 2011-04-01 2019-08-21 ImmunoGen, Inc. Methods for increasing efficacy of folr1 cancer therapy
EP2828284B1 (en) 2012-03-20 2019-05-08 Biogen MA Inc. Jcv neutralizing antibodies
DK2828292T3 (da) 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
HUE049693T2 (hu) 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
LT3038650T (lt) 2013-08-30 2021-09-10 Immunogen, Inc. Antikūnai ir foliatų receptoriaus 1 nustatymo testai
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
EP3218005B1 (en) 2014-11-12 2023-01-04 Seagen Inc. Glycan-interacting compounds and methods of use
JP6892826B2 (ja) * 2015-03-18 2021-06-23 シージェン インコーポレイテッド Ｃｄ４８抗体及びその複合体
SI3313884T1 (sl) * 2015-06-29 2021-04-30 Immunogen, Inc. Protitelesa proti CD123 ter njihovi konjugati in derivati
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MA43282A (fr) * 2015-11-19 2018-09-26 Abbvie Stemcentrx Llc Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
EP3407820A4 (en) 2016-01-26 2019-11-06 Cyberdontics, Inc. Automated dental treatment system
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
ES2903280T3 (es) * 2016-03-01 2022-03-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos del receptor de poliovirus humano (RPH)
NZ785821A (en) * 2016-03-10 2025-09-26 Viela Bio Inc Ilt7 binding molecules and methods of using the same
MA44878A (fr) 2016-04-04 2019-03-13 Bioverativ Usa Inc Anticorps anti-facteur bb du complément et utilisations de ceux-ci
CA3054939A1 (en) 2017-03-03 2018-09-07 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
AU2018323955A1 (en) 2017-08-30 2020-03-19 Phanes Therapeutics, Inc. Anti-LAG-3 antibodies and uses thereof
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
US11111297B2 (en) 2017-11-17 2021-09-07 Merck Sharp & Dohme Corp. Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
US11396538B2 (en) 2017-12-20 2022-07-26 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof
WO2019141092A1 (zh) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
EP3790492A4 (en) 2018-05-10 2022-02-09 Cyberdontics (USA), Inc. AUTOMATED DENTAL DRILL
JP7284256B2 (ja) * 2019-08-12 2023-05-30 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
JP2023505203A (ja) * 2019-12-06 2023-02-08 ビエラ バイオ インコーポレイテッド Ｉｌｔ７結合タンパク質を使用した治療方法
AR121881A1 (es) 2020-04-20 2022-07-20 Genzyme Corp Anticuerpos humanizados anti-factor bb del complemento y usos de los mismos
CN116801810A (zh) 2020-09-03 2023-09-22 网络牙科(美国)公司 用于牙齿解剖结构的cna分析的方法和装置
AU2022270101A1 (en) * 2021-05-04 2023-10-05 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
UY40376A (es) 2022-07-27 2024-01-15 Viela Bio Inc Formulaciones que comprenden una proteína de unión al transcripto 7 similar a inmunoglobulina (ilt7)
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
CN121152801A (zh) * 2023-03-16 2025-12-16 英脉生物医药(杭州)有限公司 靶向ilt7的抗体和其用途
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用
WO2026002175A1 (zh) * 2024-06-27 2026-01-02 无锡徕特康生物科技有限公司 靶向ilt7和cd89的髓细胞衔接子抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
NZ532460A (en) * 2001-10-13 2005-10-28 Asterion Ltd Glycosylphosphatidylinositol containing polypeptides
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
JP4498136B2 (ja) 2002-08-01 2010-07-07 Ｓｂｉバイオテック株式会社 マウスインターフェロン産生細胞の検出方法
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
CA2537254A1 (en) 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
US20120135003A1 (en) 2012-05-31
EP3441403A1 (en) 2019-02-13
RU2008129715A (ru) 2010-01-27
DK2532681T3 (en) 2015-01-05
KR20080090430A (ko) 2008-10-08
PL2532681T3 (pl) 2015-03-31
SI1964852T1 (sl) 2013-09-30
CN120718150A (zh) 2025-09-30
KR101585532B1 (ko) 2016-01-14
ES2699428T3 (es) 2019-02-11
HRP20130494T1 (en) 2013-08-31
CY1114227T1 (el) 2016-08-31
CN101379089B (zh) 2013-08-07
US8084585B2 (en) 2011-12-27
BRPI0620141B1 (pt) 2024-04-30
EP2532681B1 (en) 2014-10-01
WO2007072866A1 (ja) 2007-06-28
KR101624587B1 (ko) 2016-05-26
CN101379089A (zh) 2009-03-04
MX2008007682A (es) 2008-10-23
KR101526934B1 (ko) 2015-06-26
UA97946C2 (ru) 2012-04-10
HUE039865T2 (hu) 2019-02-28
PT1964852E (pt) 2013-07-10
HK1214603A1 (en) 2016-07-29
EP2913343B1 (en) 2018-08-08
KR20140053232A (ko) 2014-05-07
PT2532681E (pt) 2014-12-23
PL2913343T3 (pl) 2019-03-29
NZ569910A (en) 2012-06-29
DK2913343T3 (en) 2018-11-26
NZ599683A (en) 2013-11-29
HK1218126A1 (zh) 2017-02-03
RU2012112046A (ru) 2013-10-10
CN105111311B (zh) 2019-10-18
ME02111B (me) 2015-10-20
IL192266A (en) 2014-09-30
CA2994756A1 (en) 2007-06-28
RU2456298C2 (ru) 2012-07-20
EP1964852A4 (en) 2010-02-24
EP1964852A1 (en) 2008-09-03
EP1964852B1 (en) 2013-04-17
BRPI0620141A2 (pt) 2011-11-01
PL1964852T3 (pl) 2013-09-30
CA2634116A1 (en) 2007-06-28
SI2913343T1 (sl) 2019-01-31
RS52860B (sr) 2013-12-31
EP2532681A1 (en) 2012-12-12
CY1121294T1 (el) 2020-05-29
RU2599450C2 (ru) 2016-10-10
SG170749A1 (en) 2011-05-30
SI2532681T1 (sl) 2015-03-31
CN110776566A (zh) 2020-02-11
JP2012143232A (ja) 2012-08-02
DK1964852T3 (da) 2013-07-08
CN105111311A (zh) 2015-12-02
SG10201602095PA (en) 2016-05-30
CY1116031T1 (el) 2017-01-25
CA2994756C (en) 2020-10-27
US8470992B2 (en) 2013-06-25
US20200339682A1 (en) 2020-10-29
US20160130343A1 (en) 2016-05-12
ES2416716T3 (es) 2013-08-02
JPWO2007072866A1 (ja) 2009-06-04
CN103360492A (zh) 2013-10-23
TR201816574T4 (tr) 2018-11-21
US20130259872A1 (en) 2013-10-03
JP5420688B2 (ja) 2014-02-19
HRP20141226T1 (hr) 2015-02-27
AU2006328470B2 (en) 2012-08-16
HK1124347A1 (en) 2009-07-10
ZA200805850B (en) 2009-04-29
US20170204179A1 (en) 2017-07-20
IL192266A0 (en) 2008-12-29
RS53752B1 (sr) 2015-06-30
CA2634116C (en) 2018-03-27
JP5020828B2 (ja) 2012-09-05
ES2526079T3 (es) 2015-01-05
EP2913343A1 (en) 2015-09-02
AU2006328470A1 (en) 2007-06-28
HK1179638A1 (en) 2013-10-04
PT2913343T (pt) 2018-11-21
LT2913343T (lt) 2018-11-26
US20090280128A1 (en) 2009-11-12
CN110776566B (zh) 2025-07-15
AU2006328470A2 (en) 2008-10-09
KR20150031485A (ko) 2015-03-24

Similar Documents

Publication Publication Date Title
NZ616992A (en) Anti-ilt7 antibody
UA94060C2 (ru) Моноклональное антитело, которое специфически связывает alk-1
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
EP2143795A3 (en) Anti-CD20 monoclonal antibody
NZ621483A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
RU2010129558A (ru) ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С АЛЬФА-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
NZ615441A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
CY1107858T1 (el) Ccr5 αντισωματα pa14
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
NZ591541A (en) Pcsk9 antagonists
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
JP2003503017A5 (enExample)
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
WO2006084092A3 (en) Antibodies to oncostatin m receptor
WO2006021955A3 (en) Use of bat monoclonal antibody for immunotherapy
IL116617A0 (en) Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 20 DEC 2016 BY AJ PARK

Effective date: 20160211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2017 BY CPA GLOBAL

Effective date: 20161108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2018 BY CPA GLOBAL

Effective date: 20171102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2019 BY CPA GLOBAL

Effective date: 20181122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2020 BY CPA GLOBAL

Effective date: 20191107

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2021 BY CPA GLOBAL

Effective date: 20201105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2022 BY CPA GLOBAL

Effective date: 20211104

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2023 BY CPA GLOBAL

Effective date: 20221108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2024 BY MAXVAL GROUP INC.

Effective date: 20231205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2025 BY ANAQUA SERVICES

Effective date: 20241122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 DEC 2026 BY ANAQUA SERVICES

Effective date: 20251120